Table 4 A partial list of active clinical trials investigating therapeutic options for breast cancer patients with BCBM or LMD.

HER2+

NCT03054363

HER2i, HER2i

Tucatinib, palbociclib, and letrozole in Metastatic HR+ and HER2+ breast cancer

N

Stable

N

NCT03417544

IT, CT, HER2ab

Atezolizumab + Pertuzumab + Trastuzumab in CNS Mets

N

Both

N

NCT03501979

HER2i, HER2ab, CT

Tucatinib, Trastuzumab, and Capecitabine for the treatment of HER2+ LMD

N

Active (LMD)

Y

NCT03765983

HER2ab, PI3Ki

GDC-0084 in combination with trastuzumab for patients with HER2+ BCBM

Y

Both

N

NCT03933982

RTKi, CT

A study of pyrotinib plus vinorelbine in patients with brain metastases from HER2+ metastatic breast cancer

Y

Stable

N

NCT03975647

HER2i, HER2ab

A Study of Tucatinib vs. Placebo in Combination with Trastuzumab Emtansine (T-DM1) for patients with advanced or metastatic HER2+ breast cancer

Y

Both

N

NCT03696030

IT

HER2-CAR T cells in treating participants withbrain or leptomeningeal metastases

Y

Both

Y

NCT04420598

ADC

DS-8201a for treatment of ABC, brain metastasis, and HER2+ disease

Y

Both

Y

NCT04704661

HER2ab, STKRi

Testing the combination of DS-8201a and AZD6738, for the treatment of patients with advanced solid tumors expressing the HER2 protein or gene

Y

Stable

Y

NCT04721977

HER2i, HER2ab, CT

A study of Tucatinib (MK-7119) in combination with Trastuzumab and capecitabine in participants with previously treated locally advanced unresectable or metastatic HER2+ BC (MK-7119-001)

Y

Stable

N

NCT04739761

ADC

A study of T-DXd in participants with or without BM who have been previously treated, advanced or metastatic HER2+ BC

Y

Stable

N

HER2−

NCT03613181

PDC

ANG1005 in leptomeningeal disease from BC

N

Stable

Y

ALL

NCT03994796

–

Genetic testing in guiding treatment for patients with BM

Y

Stable

N

ALL

NCT03995706

ADC

Neuro/Sacituzumab Govitecan/BCBM/Glioblastoma

Y

Active

N

ALL

NCT04396717

Antibody

Safety study of pritumumab in brain cancer

Y

Active

Y